Mapp Biopharmaceutical was founded in 2003 by Drs. Kevin Whaley and Larry Zeitlin to develop novel pharmaceuticals for the prevention and treatment of infectious diseases, focusing on unmet needs in global health and biodefense.

The company has been developing an Ebola therapy for more than a decade and has been working with the United States and Canadian governments to develop this therapy.

As these products transition to clinical evaluation, LeafBio assumes ownership and commercialization responsibilities.